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Abstract
Background
Herpes simplex virus type 1 (HSV-1) commonly causes orolabial ulcers, while HSV-2 com-
monly causes genital ulcers. However, HSV-1 is an increasing cause of genital infection.
Previously, the World Health Organization estimated the global burden of HSV-2 for 2003
and for 2012. The global burden of HSV-1 has not been estimated.
Methods
We fitted a constant-incidence model to pooled HSV-1 prevalence data from literature
searches for 6 World Health Organization regions and used 2012 population data to derive
global numbers of 0-49-year-olds with prevalent and incident HSV-1 infection. To estimate
genital HSV-1, we applied values for the proportion of incident infections that are genital.
Findings
We estimated that 3709 million people (range: 3440–3878 million) aged 0–49 years had
prevalent HSV-1 infection in 2012 (67%), with highest prevalence in Africa, South-East Asia
and Western Pacific. Assuming 50% of incident infections among 15-49-year-olds are geni-
tal, an estimated 140 million (range: 67–212 million) people had prevalent genital HSV-1
infection, most of which occurred in the Americas, Europe and Western Pacific.
Conclusions
The global burden of HSV-1 infection is huge. Genital HSV-1 burden can be substantial but
varies widely by region. Future control efforts, including development of HSV vaccines,
should consider the epidemiology of HSV-1 in addition to HSV-2, and especially the relative
contribution of HSV-1 to genital infection.
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Introduction
Herpes simplex virus type 1 (HSV-1) is a highly infectious virus which is primarily transmitted
by oral-oral contact and causes orolabial herpes (notably “cold sores”) in those infected[1]. The
virus is highly prevalent and endemic throughout the world[2,3]. The majority of HSV-1 infec-
tions occur during childhood and infection is never cleared[1], with lifelong potential for
symptomatic or asymptomatic viral shedding episodes[4,5]. In rare cases, infection can lead to
more serious complications, such as encephalitis. In developed country settings, HSV-1 is the
most common identified cause of sporadic encephalitis in children and adults[6,7].
HSV-2, by contrast, is almost entirely sexually transmitted, and is therefore most closely
associated with genital herpes[1]. However, HSV-1 has the potential to be transmitted through
oral sex to cause genital infection[1]. In a number of developed settings (e.g., the USA, Western
Europe, Australia and New Zealand) there is evidence that the proportion of first episode geni-
tal herpes that is due to HSV-1 has increased, particularly among young people[8–13]. It is
thought that decreases in rates of childhood infection over time[14], combined with increases
in the frequency of oral sex in these populations, are driving this trend[15]. Women are more
likely to acquire genital herpes than men, and this holds true for both HSV-1 and HSV-2
[9,11,16,17].
The natural history of genital infection differs for the two viral types. Although first episode
genital herpes is clinically indistinguishable between HSV-1 and HSV-2, subsequent recurrences
are milder andmuch less frequent for HSV-1[5,18,19]. Neonatal herpes, a rare but devastating ill-
ness with high morbidity and mortality, can be caused by both HSV-1 and HSV-2[20]. However,
a study of more than 58,000 live births showed that when mothers shed genital HSV at delivery,
HSV-1 may be more likely than HSV-2 to be transmitted to the neonate[21]. In one study in
Canada from 2000–2003, 63% of neonatal herpes cases were due to HSV-1[22]. This is one of a
growing number of epidemiological studies that suggests that the impact of HSV-1 genital infec-
tions is widely underappreciated. It is known that HSV-2 increases HIV susceptibility and infec-
tiousness[23–28]. The association between HSV-1 and HIV is unknown.
Determining the proportion of HSV-1 infection that is oral versus genital is difficult. Stan-
dard type-specific serological tests measure the presence of IgG antibodies to distinguish HSV-
1 and HSV-2 infections, but can only tell us whether an individual is infected and not the site
of infection[29]. Viral shedding (both symptomatic and asymptomatic) occurring at the site of
infection can be detected by a variety of methods. However, viral shedding is episodic. This
means that viral shedding studies may not detect viral presence without multiple samples
being taken from each person over time[30]. Nevertheless, type-specific viral detection studies
remain the most accurate way to assess the site of infection.
Quantifying the overall burden of HSV-1 infection, the burden of genital HSV-1, and the
relative contribution of HSV-1 versus HSV-2 to genital herpes allows us to appropriately target
prevention and treatment resources and tailor prevention counselling. In addition, such data
can guide appropriate development of future interventions. The World Health Organization
(WHO) has generated estimates of the global burden of HSV-2 twice: for 2003[16] and for
2012[17]. The global burden of HSV-1 infection has never been estimated to our knowledge. In
this paper we present first WHO estimates of the burden of prevalent (existing) and incident
(new) HSV-1 infection in 0–49 year olds for 2012 both globally and by WHO region. We also
estimate the burden of genital HSV-1 infection in those aged 15–49 years.
Methods
The method of estimation was multi-step and very similar to the method used to generate
HSV-2 prevalence and incidence[16,17]. First we searched PubMed and EMBASE databases
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for studies reporting HSV-1 prevalence (any language) published from 2005 onwards that met
our selection criteria. For search terms used see S1 Document. HSV-1 prevalence was defined
as the percentage of individuals with type-specific IgG antibodies to HSV-1 cross-sectionally.
Reference lists of key publications were also searched. Data from publications published before
2005 and extracted previously[3,16] were included if the selection criteria were met. The key
inclusion criteria were: some detail of study location and some information on age. Studies
were excluded if participants were selected on the basis of having a medical condition. The
rationale for this was that prevalence in such individuals may not be generalizable to the gen-
eral population. For further details of the selection criteria see S1 Document.
Only prevalence values from general populations were retained for the analyses. Data from
specialised study populations such as men who have sex with men, STI clinic attendees and
commercial sex workers were not used. Studies where enrolment was based on a particular
minority subpopulation, for example, elderly Latino people in the Sacramento area, USA, were
also not used. Specific regional criteria for use in the estimates were also applied depending on
data availability by sex and study year for each region. In particular, only those prevalence val-
ues from studies from 2000 onwards were used, except for Africa and South-East Asia, where
prevalence values from 1995 onwards were used due to poor data availability.
Next we pooled raw HSV-1 prevalence values for general populations by age for each of the
6 WHO regions (and by sex where data availability permitted this). The WHO regions are as
follows: the Americas, Africa, Eastern Mediterranean, Europe, South-East Asia and Western
Pacific (S1 Table). Pooling was done for the following age ranges: 0–4; 5–9; 10–14; 15–19; 20–
24; 25–29; 30–34; 35–39; 40–44 and 45–49 years. A sample size of 20 or more was required for
pooling. All prevalence values were adjusted for test sensitivity and specificity prior to pooling
[31–33].
Lastly we fitted a model[34] to the pooled HSV-1 prevalence values to estimate smoothed
HSV-1 prevalence and calibrate HSV-1 incidence, which were then applied to population sizes
for 2012[35] to generate the regional burdens of HSV-1 infection at any site. We estimated the
burden of genital HSV-1 infection by assigning values for the proportion of incident HSV-1
infections from age 15 years that are genital from existing literature. This proportion is difficult
to determine, and to our knowledge, only two studies have been carried out to estimate it. In a
prospective US study of HSV-2 seronegative individuals aged 17–79 years who were “high-
risk” or in HSV-2 serodiscordant relationships, 19 had incident HSV-1 infections, of which 12
were symptomatic and the site of infection could be determined. Overall, 50% (6/12) of symp-
tomatic incident HSV-1 infections were associated with genital lesions; the remaining symp-
tomatic individuals had either orolabial lesions or pharyngitis[36]. In a more recent study of
HSV seronegative women aged 18–30 years in the control arm of the HERPEVAC Trial for
Women in the USA, with 127 total incident HSV-1 infections, 85% (28/33) of symptomatic
incident HSV-1 infections were associated with either genital disease or both oral and genital
disease[13]. We found no studies to estimate this proportion outside of the USA.
Uncertainty bounds around the estimates were computed which accounted for uncertainty
in the underlying prevalence data. For a detailed description of the model and estimates calcu-
lation see S1 Document.
Ethics Statement
It was not necessary to seek ethical approval for this study as this study is an analysis of existing
published prevalence data and as such did not involve human participants directly. Corre-
spondingly, no patient records or patient information were accessed.
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Results
Data availability
A total of 2943 publications were identified in the literature search (Fig 1). After exclusion of
400 duplicates, the abstracts of the 2543 remaining publications were checked. This led to
exclusion of a further 1904 publications due to non-relevance. The full texts of the resulting
639 publications were obtained and checked, along with 13 potentially-relevant publications
identified from reference lists. Few studies reporting incidence necessitated using observed
prevalence to calibrate incidence; however modelled incidences were checked against reported
values and found to be in line. Fifty-four publications on 45 separate studies reported HSV-1
prevalence in general populations and met all of our general selection criteria. Of these 45 stud-
ies, 22 studies were done in populations with age between 0–49 years and met the region-spe-
cific criteria for inclusion in the estimates (S2 Table), along with a further 15 studies from
earlier reviews (S1 Database and S1 Reference List).
Thirty-seven studies from 27 countries contributed 164 prevalence observations by age and
a total of 40,605 individuals, of which 141 prevalence observations (34,556 individuals) were
used in the estimates (S3 Table and S4 Table). Studies were represented more than once if they
reported prevalence for more than one age group. Prevalence observations were more abun-
dant for the Americas and Europe, whereas in other regions some age ranges did not have prev-
alence estimates. In particular, small numbers of studies in children hampered accurate model
fitting for younger ages. Additionally, within-region estimates were often heterogeneous (S4
Table).
Each HSV-1 assay used was assigned a sensitivity and specificity value based on published
evaluations to adjust prevalence (S5 Table). Focus Diagnostics' HerpeSelect assay (Cypress,
CA) was the most commonly used assay to diagnose individuals as HSV-1 seropositive or
seronegative.
Prevalent HSV-1 infection in 2012
The estimated worldwide prevalence of HSV-1 infection among 0–49 year olds in 2012 was
67% averaged across all ages (Table 1). Prevalence increased with age, and was high across all
regions, but highest in Africa (87% overall prevalence) and lowest in the Americas (40–50%)
(Table 1 and Fig 2). HSV-1 prevalence seemed to reach saturation by adolescence in Africa and
South-East Asia, and by early adulthood in Eastern Mediterranean. In contrast, prevalence
continued to increase throughout adulthood in the Americas, Europe and Western Pacific, and
saturated much later, if at all (Fig 2). Overall, there were an estimated 3709 million individuals
aged 0–49 years with prevalent HSV-1 infection worldwide in 2012 (Table 1). The number was
highest in Africa, South-East Asia andWestern Pacific, reflecting large population size.
For the Americas and Europe, for which model fitting was done separately by sex, the fitted
HSV-1 prevalence was slightly lower in males compared to females (Figs 2A and 2D). This was
true across all ages (except at oldest age), including childhood. The difference in children may
have been in part an artefact of model fitting using limited available data: the best model fits to
prevalence differences by sex among adults resulted in unequal fitted prevalence by sex among
children.
Incident HSV-1 infection in 2012
The total number of new infections in 2012 was estimated to be 118 million (Table 2). Again,
the number was highest for those regions where population size was highest: Africa, South-
East Asia andWestern Pacific. Most HSV-1 infections occurred during the first five years of
Global Estimates of Herpes Simplex Virus Type 1 Infections in 2012
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Fig 1. Number of studies at each stage of the literature search and study selection process.
doi:10.1371/journal.pone.0140765.g001
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life in Africa and South-East Asia, with virtually no new infection in adulthood. Around two-
thirds of HSV-1 infections occurred in those aged 0–5 years in Eastern Mediterranean, half in
Western Pacific, and one-third in Europe. By contrast, around half of new HSV-1 infections in
the Americas occurred in those aged 15–49 years (Table 2).
Table 1. Global and regional estimates of the number of existing (prevalent) cases of HSV-1 infection in 2012 by age and sex, in millions (percent-
age of population with prevalent infection shown in parentheses).
Both sexes
Age group (years)
0–4 5–9 10–14 15–19 20–24 25–29 30–34 35–39 40–44 45–49 All ages
Global total (all) 175
(27%)
353
(57%)
392
(66%)
420
(71%)
453
(74%)
439
(75%)
394
(76%)
378
(77%)
367
(78%)
337
(79%)
3709
(67%)
Females
Age group (years)
Region 0–4 5–9 10–14 15–19 20–24 25–29 30–34 35–39 40–44 45–49 All ages
Americas 3 9 14 18 21 22 23 23 23 23 178
(49%)
Africa 36 57 52 45 40 35 29 23 18 15 350
(87%)
Eastern
Mediterranean
9 20 24 25 25 24 20 16 14 12 188
(75%)
Europe 5 12 16 19 24 26 26 26 26 27 207
(69%)
South-East Asia 24 49 53 52 51 49 45 41 37 32 432
(59%)
Western Paciﬁc 11 27 36 48 65 63 53 60 65 59 488
(74%)
Global total
(females)
86 175 194 208 225 219 196 188 183 168 1843
(68%)
Males
Age group (years)
Region 0–4 5–9 10–14 15–19 20–24 25–29 30–34 35–39 40–44 45–49 All ages
Americas 2 6 10 14 16 18 19 19 19 20 142
(39%)
Africa 37 58 53 46 40 35 29 23 18 15 355
(87%)
Eastern
Mediterranean
9 22 25 26 27 26 22 18 15 13 202
(75%)
Europe 3 8 12 16 21 24 25 25 26 26 187
(61%)
South-East Asia 26 53 57 56 54 51 47 42 38 34 458
(58%)
Western Paciﬁc 12 31 41 54 70 67 55 62 68 62 521
(73%)
Global total (males) 89 179 198 212 228 220 197 189 184 169 1866
(66%)
Totals may be slightly different due to rounding. Sex-speciﬁc estimates for Africa, Eastern Mediterranean, South-East Asia and Western Paciﬁc were
generated by applying modelled prevalence, ﬁtted without stratiﬁcation by sex, to sex-speciﬁc population sizes. Slight differences in prevalence averaged
across all ages between the sexes for these regions are therefore due to different population sizes by sex.
doi:10.1371/journal.pone.0140765.t001
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Genital HSV-1 infection in 2012
An estimated 140 million people aged 15–49 years were calculated to have prevalent genital
HSV-1 infection globally in 2012, assuming 50% of incident infections in this age group were
genital, and up to 239 million people if 85% of new HSV-1 infections were genital (Table 3).
Patterns of genital HSV-1 infection by age, sex and region were unaffected by changing the
assumption of genital incident infection. The Americas and Western Pacific contributed the
Fig 2. Model fits to pooled HSV-1 prevalence values by age for (A) the Americas, (B) Africa, (C) Eastern Mediterranean, (D) Europe, (E) South-East
Asia and (F) Western Pacific, to generate smoothed HSV-1 prevalence and calibrate HSV-1 incidence for the HSV-1 estimates.Confidence intervals
are not shown for the pooled prevalence values for those regions for which data without finite age limits and/or with estimated sample size were additionally
used in the pooling (Eastern Mediterranean and South-East Asia), or where individual prevalence values were used for the model fitting in addition to pooled
values (Africa).
doi:10.1371/journal.pone.0140765.g002
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most genital HSV-1 cases: the Americas by virtue of highest genital HSV-1 prevalence, and
Western Pacific by virtue of large population size and medium prevalence. Higher genital
HSV-1 incidence was reflective of adult versus childhood acquisition. Thus, Africa and South-
East Asia seemed to have negligible genital HSV-1.
The higher overall HSV-1 prevalence on entering adolescence and earlier saturation in prev-
alence in females compared to males in Europe in the model fits, and to a lesser extent in the
Americas, meant higher genital HSV-1 prevalence was reached among males compared to
females. Again this may have been, at least in part, an artefact of fitting the model to limited
available data, generating unequal prevalence in childhood.
Genital herpes due to HSV-1 versus HSV-2 in 2012
Collating the numbers of individuals with genital HSV-1 and HSV-2 infection, and adjusting
for the expected number of individuals with co-infection (if HSV-2 infection is completely pro-
tective against subsequent genital HSV-1 infection[36,37], but prior genital HSV-1 infection
does not afford any protection against HSV-2 infection[2]), gave an estimate for the total,
global number of individuals aged 15–49 years with prevalent genital HSV infection in 2012
of 544 million (15% prevalence) (Table 4). This calculation assumed 50% of incident HSV-1
infections in this age group are genital; assuming 85% of HSV-1 infections are genital resulted
Table 2. Global and regional estimates of the number of new (incident) cases of HSV-1 infection in 2012 by age and sex, in millions (percentage of
population with incident infection shown in parentheses).
Both sexes
Age group (years)
0–4 5–9 10–14 15–19 20–24 25–29 30–34 35–39 40–44 45–49 All ages
Global total (all) 79 (12%) 19 (3%) 8 (1%) 4 (0.8%) 3 (0.5%) 2 (0.3%) 1 (0.2%) 0.9 (0.2%) 0.7 (0.1%) 0.5 (0.1%) 118 (2%)
Females
Age group (years)
Region 0–4 5–9 10–14 15–19 20–24 25–29 30–34 35–39 40–44 45–49 All ages
Americas 1.351 1.082 0.865 0.681 0.529 0.406 0.302 0.224 0.167 0.128 6 (2%)
Africa 15.626 1.412 0.129 0.012 0.001 0.000 0.000 0.000 0.000 0.000 17 (4%)
Eastern Mediterranean 4.132 1.460 0.533 0.201 0.076 0.028 0.009 0.003 0.001 0.000 6 (3%)
Europe 2.148 1.103 0.583 0.348 0.221 0.128 0.068 0.036 0.020 0.011 5 (2%)
South-East Asia 10.503 1.828 0.313 0.053 0.009 0.001 0.000 0.000 0.000 0.000 13 (2%)
Western Paciﬁc 5.078 2.480 1.295 0.802 0.531 0.265 0.116 0.068 0.039 0.019 11 (2%)
Global total (females) 39 9 4 2 1 0.8 0.5 0.3 0.2 0.2 57 (2%)
Males
Age group (years)
Region 0–4 5–9 10–14 15–19 20–24 25–29 30–34 35–39 40–44 45–49 All ages
Americas 0.900 0.811 0.730 0.644 0.555 0.472 0.390 0.318 0.264 0.226 5 (1%)
Africa 16.032 1.444 0.131 0.012 0.001 0.000 0.000 0.000 0.000 0.000 18 (4%)
Eastern Mediterranean 4.360 1.544 0.564 0.212 0.081 0.030 0.010 0.003 0.001 0.000 7 (3%)
Europe 1.367 0.947 0.675 0.542 0.459 0.353 0.250 0.178 0.128 0.095 5 (2%)
South-East Asia 11.459 1.996 0.341 0.057 0.009 0.002 0.000 0.000 0.000 0.000 14 (2%)
Western Paciﬁc 5.779 2.811 1.452 0.891 0.577 0.281 0.121 0.070 0.041 0.019 12 (2%)
Global total (males) 40 10 4 2 2 1 0.8 0.6 0.4 0.3 61 (2%)
Totals may be slightly different due to rounding. Sex-speciﬁc estimates for Africa, Eastern Mediterranean, South-East Asia and Western Paciﬁc were
generated by applying modelled incidence, calibrated without stratiﬁcation by sex, to sex-speciﬁc population sizes. Region-speciﬁc estimates are given to
3 d.p. due to some small numbers of infected individuals, but this level of accuracy is unlikely to be supported by the model.
doi:10.1371/journal.pone.0140765.t002
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Table 3. Global and regional estimates of the number of existing (prevalent) cases of genital HSV-1 infection among 15–49 year olds in 2012 by
age and sex, in millions (percentage of population with prevalent infection shown in parentheses), as a function of the assumed proportion of inci-
dent HSV-1 infections in this age group that are genital.
ASSUMING 50% OF INCIDENT HSV-1 INFECTIONS AMONG 15–49 YEAR OLDS ARE GENITAL
Both sexes
Age group (years)
15–19 20–24 25–29 30–34 35–39 40–44 45–49 All ages
Global total (all) 5 (0.8%) 15 (2%) 21 (3%) 22 (4%) 25 (5%) 27 (6%) 27 (6%) 140 (4%)
Females
Age group (years)
Region 15–19 20–24 25–29 30–34 35–39 40–44 45–49 All ages
Americas 0.697 2.184 3.275 3.954 4.358 4.623 4.859 24 (10%)
Africa 0.013 0.022 0.020 0.017 0.013 0.011 0.009 0.1 (0.0%)
Eastern Mediterranean 0.217 0.533 0.614 0.556 0.458 0.390 0.341 3 (2%)
Europe 0.368 1.189 1.698 1.889 1.982 2.030 2.123 11 (5%)
South-East Asia 0.059 0.118 0.123 0.115 0.104 0.094 0.083 0.7 (0.1%)
Western Paciﬁc 0.849 2.931 3.713 3.492 4.117 4.626 4.253 24 (5%)
Global total (females) 2 7 9 10 11 12 12 63 (3%)
Males
Age group (years)
Region 15–19 20–24 25–29 30–34 35–39 40–44 45–49 All ages
Americas 0.651 2.108 3.279 4.091 4.608 5.018 5.455 25 (10%)
Africa 0.014 0.022 0.020 0.017 0.014 0.011 0.009 0.1 (0.0%)
Eastern Mediterranean 0.229 0.568 0.666 0.617 0.513 0.426 0.360 3 (2%)
Europe 0.558 1.986 3.109 3.726 4.137 4.437 4.737 23 (10%)
South-East Asia 0.064 0.124 0.128 0.120 0.108 0.098 0.086 0.7 (0.1%)
Western Paciﬁc 0.943 3.186 3.930 3.630 4.252 4.820 4.427 25 (5%)
Global total (males) 2 8 11 12 14 15 15 77 (4%)
ASSUMING 85% OF INCIDENT HSV-1 INFECTIONS AMONG 15–49 YEAR OLDS ARE GENITAL
Both sexes
Age group (years)
15–19 20–24 25–29 30–34 35–39 40–44 45–49 All ages
Global total (all) 8 (1%) 25 (4%) 35 (6%) 38 (7%) 42 (9%) 45 (10%) 45 (11%) 239 (6%)
Females
Age group (years)
Region 15–19 20–24 25–29 30–34 35–39 40–44 45–49 All ages
Americas 1.184 3.712 5.568 6.721 7.409 7.859 8.261 41 (17%)
Africa 0.023 0.038 0.034 0.029 0.023 0.018 0.015 0.2 (0.1%)
Eastern Mediterranean 0.369 0.907 1.044 0.945 0.778 0.664 0.581 5 (3%)
Europe 0.625 2.022 2.887 3.211 3.370 3.450 3.609 19 (9%)
South-East Asia 0.100 0.200 0.208 0.196 0.177 0.160 0.141 1 (0.2%)
Western Paciﬁc 1.443 4.982 6.313 5.936 7.000 7.864 7.231 41 (8%)
Global total (females) 4 12 16 17 19 20 20 107 (6%)
Males
Age group (years)
Region 15–19 20–24 25–29 30–34 35–39 40–44 45–49 All ages
Americas 1.107 3.584 5.575 6.954 7.834 8.530 9.274 43 (18%)
Africa 0.023 0.038 0.034 0.029 0.023 0.018 0.015 0.2 (0.1%)
Eastern Mediterranean 0.390 0.966 1.133 1.049 0.872 0.725 0.612 6 (3%)
Europe 0.948 3.376 5.286 6.333 7.033 7.543 8.053 39 (17%)
(Continued)
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in 633 million cases (17% prevalence). Of these, an estimated 322–360 million were women
and 223–273 million were men. Region-specific analysis showed that different dynamics can
result in similar overall HSV prevalence (Tables 3 and 4). For example, Africa and the Ameri-
cas both had high genital herpes prevalence (>19%), but for quite different reasons: prevalence
of genital HSV-1 was estimated to be>9% in the Americas versus ~0% in Africa, while Africa
had higher HSV-2 prevalence.
Uncertainty analysis
The 95% credible range for the number of individuals aged 0–49 years with any prevalent
HSV-1 infection worldwide in 2012 was calculated to be 3440–3878 million: 1709–1931 million
women and 1728–1965 men (Table 5). The equivalent 95% credible range for the global num-
ber aged 15–49 years with prevalent genital HSV-1 infection in 2012 was dependent on the
assumed proportion of incident HSV-1 infections at these ages that were genital, and varied
from 67–212 million when this proportion was 50%, and from 113–361 million when it was
85% (Table 5). The credible ranges were very wide for all regions (except Africa, for which the
computed credible range was not reliable due to insufficient pooled prevalence values to sam-
ple). Thus, plausible changes in the underlying prevalence data informing the model fits can
generate very different patterns of infection, including earlier saturation in overall HSV-1
prevalence and little subsequent genital HSV-1 in the Americas (although the majority of runs
gave estimates for genital HSV-1 at the upper end), and later saturation in overall HSV-1 and
substantial genital HSV-1 in Eastern Mediterranean and South-East Asia (although the major-
ity of runs gave estimates for genital HSV-1 at the lower end).
Discussion
An estimated 3709 million people globally aged 0–49 years were infected with prevalent HSV-1
in 2012. Assuming 50% of incident infections among 15-49-year-olds are genital, an estimated
140 million people were infected with prevalent genital HSV-1. The number of HSV-1 infec-
tions was highest for Africa, South-East Asia andWestern Pacific, which had the largest popu-
lation sizes. However, the majority of genital HSV-1 infections were in the Americas, Europe
andWestern Pacific, where HSV-1 infection continued to increase after adolescence. The prev-
alence of genital HSV-1 was highest for the Americas, which had the lowest HSV-1 prevalence
on entering adolescence of all 6 regions.
Taken together with estimates of HSV-2 infection among adults globally, which were all
considered to be genital, our new estimates of HSV-1-associated genital infection suggested
that 544 million people had genital infection due to either viral type worldwide in 2012, assum-
ing half of incident HSV-1 infections in adults are genital. This figure could be as high as 633
million people, if 85% of incident HSV-1 infections in adults are genital, as suggested in a
recent prospective study(13). It is unclear how much of this infection is recognized, as only
about 10–20% of HSV-2 infections are diagnosed[14,38,39] and the analogous proportion for
Table 3. (Continued)
South-East Asia 0.108 0.212 0.218 0.204 0.183 0.166 0.147 1 (0.2%)
Western Paciﬁc 1.604 5.416 6.680 6.171 7.229 8.194 7.526 43 (8%)
Global total (males) 4 14 19 21 23 25 26 131 (7%)
Totals may be slightly different due to rounding. Region-speciﬁc estimates are given to 3 d.p. due to some small numbers of infected individuals, but this
level of accuracy is unlikely to be supported by the model.
doi:10.1371/journal.pone.0140765.t003
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HSV-1 is unknown. In adults and adolescents, genital herpes due to HSV-1 is associated with
less frequent symptomatic disease recurrences than HSV-2[5,18,19]. Thus, disease burden will
vary by region not only by the number of people with genital herpes, but also the relative pro-
portions caused by HSV-2 versus HSV-1.
Although the burden of genital HSV-2 is high in Africa and moderate in South-East Asia,
the available data suggest that genital HSV-1 is currently less likely to be an important public
health problem in these regions. This is because HSV-1 acquisition here appeared to be high
prior to adolescence and thus sexual debut, thereby protecting individuals in these regions
from genital disease. However, the prevalence data on which the estimates were based were
extremely sparse. For Africa, only one pooled prevalence estimate was available, with the
remainder of the prevalence data for fitting coming from single studies. Genital HSV-1 could
be much higher than estimated if HSV-1 infection continued after adolescence in these regions.
Table 4. Global and regional estimates of the prevalence of, and total number of individuals with, genital herpes infection due to either HSV-1 or
HSV-2 among 15–49 year olds in 2012, by sex, as a function of the assumed proportion of incident HSV-1 infections in this age group that are
genital.
ASSUMING 50% OF INCIDENT HSV-1 INFECTIONS AMONG 15–49 YEAR OLDS ARE GENITAL
Females Males
Region Prevalence of genital
HSV infection (%)
Number with HSV-1 or
HSV-2 genital infection
(millions)
Region Prevalence of genital
HSV infection (%)
Number with HSV-1 or
HSV-2 genital infection
(millions)
Americas 26 65 Americas 20 48
Africa 38 81 Africa 25 54
Eastern
Mediterranean
14 22 Eastern
Mediterranean
5 9
Europe 14 32 Europe 14 31
South-East Asia 9 42 South-East Asia 7 34
Western Paciﬁc 16 80 Western Paciﬁc 9 47
Global total
(females)
18 322 Global total
(males)
12 223
Global total (all) 544 million (15%)
ASSUMING 85% OF INCIDENT HSV-1 INFECTIONS AMONG 15–49 YEAR OLDS ARE GENITAL
Females Males
Region Prevalence of genital
HSV infection (%)
Number with HSV-1 or
HSV-2 genital infection
(millions)
Region Prevalence of genital
HSV infection (%)
Number with HSV-1 or
HSV-2 genital infection
(millions)
Americas 32 78 Americas 26 63
Africa 38 81 Africa 25 54
Eastern
Mediterranean
15.5 24 Eastern
Mediterranean
6.5 11
Europe 18 39 Europe 21 47
South-East Asia 9 42 South-East Asia 7 35
Western Paciﬁc 19 95 Western Paciﬁc 12 64
Global total
(females)
20 360 Global total
(males)
15 273
Global total (all) 633 million (17%)
Totals may be slightly different due to rounding. Prevalence (and corresponding numbers infected) reduced by estimated fraction of infections that are co-
infections (genital HSV-1 prevalence * HSV-2 prevalence) to avoid double counting, assuming that genital HSV-1 does not occu after HSV-2 infection,
and that HSV-2 infection is independent of previous infection with genital HSV-1. Note that this table is for infection, not disease.
doi:10.1371/journal.pone.0140765.t004
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Additionally, regional estimates could mask very different patterns of infection, including
higher genital HSV-1, in individual countries or in specific settings.
Our estimates of HSV-1 are considerably hampered by small numbers of studies across all
regions, and by issues of small sample size, quality of data and generalizability within studies.
Estimates of the burden of genital HSV-1 are severely hampered by lack of data on the propor-
tion of incident HSV-1 infection from adolescence that is genital. We attempted to account for
this uncertainty by generating two sets of estimates for genital HSV-1: the first assuming a
Table 5. 95% credible bounds for the global and regional estimates of the number of cases of any prevalent HSV-1 infection, and prevalent genital
HSV-1 infection, in 2012 by sex, in millions, incorporating uncertainty in the underlying HSV-1 prevalence data, and as a function of the assumed
proportion of incident HSV-1 infections in this age group that are genital.
Both sexes
Prevalent HSV-1 infection (any
site)
Prevalent genital HSV-1 infection
(assuming 50% of incident
infections are genital from age
15)
Prevalent genital HSV-1 infection
(assuming 85% of incident
infections are genital from age
15)
Lower bound Upper bound Lower bound Upper bound Lower bound Upper bound
Global total (all) 3440 3878 67 212 113 361
Females
Prevalent HSV-1 infection (any
site)
Prevalent genital HSV-1 infection
(assuming 50% of incident
infections are genital from age
15)
Prevalent genital HSV-1 infection
(assuming 85% of incident
infections are genital from age
15)
Region Lower bound Upper bound Lower bound Upper bound Lower bound Upper bound
Americas 148 211 0.04 29.06 0.06 49.41
Africa 335a 355a 0.05a 0.14a 0.09a 0.23a
Eastern Mediterranean 152 210 0.03 13.89 0.06 23.62
Europe 173 228 1.63 25.70 2.77 43.70
South-East Asia 348 505 0.06 12.30 0.11 20.91
Western Paciﬁc 420 528 0.25 56.32 0.43 95.74
Global total (females) 1709 1931 26 103 44 174
Males
Prevalent HSV-1 infection (any
site)
Prevalent genital HSV-1 infection
(assuming 50% of incident
infections are genital from age
15)
Prevalent genital HSV-1 infection
(assuming 85% of incident
infections are genital from age
15)
Region Lower bound Upper bound Lower bound Upper bound Lower bound Upper bound
Americas 115 174.5 0.03 27.14 0.06 46.14
Africa 339a 359a 0.05a 0.14a 0.09a 0.23a
Eastern Mediterranean 164 225 0.04 15.13 0.06 25.71
Europe 153 213 0.36 27.84 0.60 47.33
South-East Asia 370 536 0.07 12.87 0.11 21.87
Western Paciﬁc 448 565 0.27 59.03 0.45 100.34
Global total (males) 1728 1965 33 113 56 192
95% credible bounds for each regional set of estimates (by sex) were computed as follows. Firstly we sampled each pooled HSV-1 prevalence value 1000
times assuming a normal distribution, using the standard deviation derived from the meta-analysis. Next, we recalibrated λ and k for each set of sampled
pooled prevalence values by region (by sex for the Americas and Europe). The resulting set of 1000 estimates was then sorted low-high for each
estimate, sex and region of interest and the 2.5 and 97.5 percentile estimates extracted for the lower and upper uncertainty bounds. Region-speciﬁc
estimates for genital HSV-1 are given to 2 d.p. due to some small numbers of infected individuals, but this level of accuracy is unlikely to be supported by
the model. Note that stratiﬁed ranges do not sum to unstratiﬁed ranges.
aCredible range not reliable due to limited sampling of pooled prevalence.
doi:10.1371/journal.pone.0140765.t005
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value of 50% for this proportion[36], and the second assuming a value of 85%[13]. These values
are the best available, but based on very small samples and only US populations. In addition,
the site of new HSV-1 infection can only be determined for symptomatic people, and a large
proportion of infections are asymptomatic. The estimates assume that the proportions of new
HSV-1 infections that are genital versus oral are the same for both symptomatic and asymp-
tomatic people. If new genital HSV-1 infections are more likely than new oral HSV-1 infections
to be symptomatic, the estimated proportion of all incident HSV-1 infections that are genital
may be inflated. This proportion may also vary considerably by region, setting, age and sex,
although this variability may be less important for regions like Africa and South-East Asia with
apparently little HSV-1 acquisition after early adolescence. Although we computed uncertainty
bounds around the estimates, these are unlikely to fully account for all variation in underlying
prevalence, most notably because reliable bounds for the African estimates could not be calcu-
lated. Consideration of the estimate reliability in light of these important issues should accom-
pany interpretation and application of these estimates.
Recent changes in the pattern of HSV-1 infection, i.e., decreasing rates of oral HSV-1 infec-
tion in childhood and increasing sexual transmission of HSV-1, mean that there may be cohort
effects in prevalence data whereby older individuals have experienced higher historic rates of
childhood infection and lower rates of sexual transmission. In the National Health and Nutri-
tion Examination Surveys (NHANES) in the USA, the only nationally-representative general
population surveys of HSV-1 prevalence repeated over a number of years, HSV-1 seropreva-
lence has been declining since the first surveys (1988–1994) and is continuing to decrease, with
the largest decreases observed for adolescents[14,40]. We used only data from 2000 onwards
(with the exception of Africa and South-East Asia), which minimized the influence of cohort
effects to some extent. However this would not have removed the effect of all ongoing HSV-1
trends in the Americas and potentially other settings. The model in effect enables us to fit a
function to smooth out observed prevalence, and then estimate the number of incident infec-
tions that would result from the fitted function, assuming that over the short period of one year
prevalence does not change.
Impact and recommendations
This is the first attempt to calculate the global burdens of all HSV-1 and genital HSV-1, and
hence the first attempt to quantify the extent to which genital HSV-1 presents a public health
problem across different regions. To date, prevention and control efforts against genital herpes
have focussed almost exclusively on HSV-2. We show that this strategy is likely to be currently
appropriate for Africa and South-East Asia, where genital HSV-1 infection is probably not a pub-
lic health issue at this time. However, for other regions, most notably the Americas, Europe and
Western Pacific, such a strategy would fail to address a substantial burden of genital HSV-1 infec-
tion. In addition to the consequences of genital HSV-1 infection, orolabial HSV-1 infection is
important in its own right. Symptomatic recurrent orolabial herpes can range from a mere
annoyance to severe disease in the setting of immunocompromise. In addition, HSV-1 is one of
the most common causes of sporadic encephalitis, which is rare but devastating, with high mor-
bidity and associated costs[6,7] and HSV-1 also contributes to neonatal infections and deaths.
Patterns of HSV-1 and HSV-2 infection, and their relative contribution to genital disease,
are a product of multiple interactions. These include: different routes of transmission, different
risk profiles by age, and the role of cross-immunity. Decreases in childhood HSV-1 infection
and increases in orogenital sex have the potential to introduce genital HSV-1 as a public health
issue in those regions where it is currently minimally present, since decreasing childhood-
acquired immunity to HSV-1 (oral HSV-1 otherwise seems to protect against genital HSV-1)
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means more adults are at risk of acquiring genital HSV-1 through oral sex. Since HSV-1 infec-
tion does not seem to follow HSV-2[37], interventions that decrease HSV-2 infection could
potentially lead to an increase in genital HSV-1, while a decrease in HSV-1 could lead to an
increase in HSV-2 disease[36]. Other considerations for control programmes include: genital
herpes due to HSV-1 is less likely to recur compared with HSV-2; the risk of neonatal herpes
seems to be higher for HSV-1 than for HSV-2; and genital HSV-1 could in theory enhance
HIV acquisition in a similar way to HSV-2 although the association is not understood.
Despite the limited availability of data informing these estimates, we hope to increase
understanding of the global scope of HSV-1 infection, and guide development of future pre-
vention efforts. In a recent Phase III trial, an HSV vaccine based on glycoprotein D2 failed to
prevent HSV-2 infection and disease, but, encouragingly, did show significant efficacy against
HSV-1-related infection and disease[41]. Efforts to develop new HSV vaccines are advancing
[42]. There are currently a number of HSV vaccine candidates in the development pipeline,
with several therapeutic (vaccines which work in those already infected to reduce viral shed-
ding and disease) and prophylactic vaccines in Phase I and II trials, in conjunction with sub-
stantial advances in delivery systems, adjuvants and stimulation of mucosal immunity[42].
These estimates lay the groundwork for determining the potential impact of a vaccine against
HSV and informing important vaccine characteristics. For the Americas, Europe and the West-
ern Pacific, a vaccine would need to target both HSV types to prevent genital herpes. In Africa
and South-East Asia, a vaccine targeting HSV-2 infection would address genital herpes but
would need to be effective in the presence of HSV-1 infection if targeted to adolescents or
would need to be an infant vaccine.
In summary, these WHO estimates show an enormous burden of HSV-1 globally, with
regional variation in the age at which HSV-1 is acquired. Increased data on the epidemiology
of HSV-1 are needed to strengthen the robustness of these estimates and provide a clearer pic-
ture in all regions as to how HSV-1 differs by age and sex. Furthermore, an improved under-
standing of the interaction between HSV-1 and HSV-2 at different anatomic sites on protective
immunity is needed. Genital HSV-1 acquisition is lowest in regions such as Africa with the
highest HIV rates, but understanding how HSV-1 affects HIV spread is critical given how com-
mon this infection is globally. It is hoped these estimates will be used to develop appropriate
prevention messages, manage and counsel patients with symptomatic genital herpes, develop
improved treatment regimens and diagnostic tests, and ultimately, develop HSV vaccines.
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